Monoterpenes and their derivatives as agents for cardiovascular disease management: A systematic review and meta-analysis
| Autor: | Eric Aian Pereira Da Silva, André S. Barreto, Diego Santos Souza, Igor Alexandre Côrtes de Menezes, Márcio R. V. Santos, Fernanda Oliveira de Carvalho, Danillo Menezes Dos Santos, Lucindo José Quintans-Júnior |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Aromatic plants
Myocardial Infarction Pharmaceutical Science Disease Bioinformatics 03 medical and health sciences 0302 clinical medicine Drug Discovery Oils Volatile Medicine Animals Humans Disease management (health) 030304 developmental biology Pharmacology 0303 health sciences business.industry Cardiovascular Agents Plants Disease Models Animal Clinical research Complementary and alternative medicine Drug development Cardiovascular Diseases 030220 oncology & carcinogenesis Meta-analysis Cardiac hypertrophy Cardiovascular agent Hypertension Monoterpenes Molecular Medicine business |
| Zdroj: | Phytomedicine : international journal of phytotherapy and phytopharmacology. 88 |
| ISSN: | 1618-095X |
| Popis: | Background Monoterpenes are one of the most studied plant's secondary metabolites, they are found abundantly in essential oils of aromatic plants. They also have a great range of pharmacological properties, such as antihypertensive, bradycardic, antiarrhythmic and hypotensive. In the face of the burden caused by cardiovascular disease (CVDs) worldwide, studies using monoterpenes to assess their cardiovascular effects have increased over the years. Purpose This systematic review aimed to summarize the use of monoterpenes in animal models of any CVDs. Methods PubMed, SCOPUS, LILACS and Web of Science databases were used to search for articles that used monoterpenes, in any type of administration, to treat or prevent CVDs in animal models. The PRISMA guidelines were followed. Two independent researchers extracted main characteristics of studies, methods and outcomes. Data obtained were analyzed qualitatively and quantitatively. Results At the ending of the search process, 33 articles were selected for the systematic review. Of these, 17 articles were included in the meta-analysis. A total of 16 different monoterpenes were found for the treatment of hypertension, myocardial infarction, pulmonary hypertension, cardiac hypertrophy and arrhythmia. The main actions include hypotension, bradycardia, vasodilatation, antiarrhythmic, and antioxidant and antiapoptotic properties. From our data, it can be suggested that monoterpenes may be a significant source for new drug development. However, there is still a need to apply these knowledge into clinical research and a long path to pursue before putting them in the market. Conclusion The variability of cardiovascular effects demonstrated by the monoterpenes highlighted them as a promising candidates for treatment or prevention of CVDs. Nevertheless, studies that investigate their biological sites of action needs to be further encouraged. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect